The Tissue Biospecimen and Pathology Resource (TBPR) is comprised of mature, highly functional CCSG supported shared facilities and provides all basic science, translational, clinical, and population science investigators at MD Anderson with access to human tissues that have been removed by therapeutic resection or biopsy with research consent, and advanced histologic services for characterization of human and animal research tissues. The TBPR supports hypothesis-generating, -developing, and -testing studies, including both correlative and integrated marker studies in clinical trials. The TBPR biorepository has six -80 freezers and three isothermal liquid nitrogen freezers in its centralized and monitored storage facility, and a - 80 freezer in each of the two Surgical Pathology suites. The TBPR research histology core includes specialized equipment for immunohistochemistry, fluorescent in situ hybridization (FISH), laser capture microdissection, and tissue microarray construction. 190,235 tissue specimens from 37,296 cases were collected during the current reporting period for Yrs 33-38, and 63,288 specimens were distributed to 152 investigators. Research histology usage grew by 5.2% from 174,015 units in 2007-2008 to 183,134 in 2011- 2012. Of the 152 total individual users of the TBPR biorepository, 86% of users had peer-reviewed funding, and 81.2% of 422 TBPR research histology users had peer-reviewed funding. 42% of the total operating budget for the TBPR is requested from the CCSG. Publications cited using the CCLC have appeared in Nature, Nature Med and J Clin Oncol. Institutional administrative support was provided by the Research Support Office in the Division of Pathology &Laboratory Medicine. Future plans include: establishing collaborative efforts with Lyndon B. Johnson Hospital and Banner MD Anderson to increase specimen collections from underserved and community patient populations;increasing sterile tissue collection and processing for vaccine clinical trials;increasing specimen collection in clinic procedure rooms and Interventional Radiology;collaborating with the Office of Biorepository Regulatory Support to standardize operations in all federated biorepositories at MD Anderson;enhancing Tissue Station integration with clinical and research protocol management databases;increasing the roster of available tissue biomarkers;and implementing a more efficient and multifunctional Laboratory Information Management System for charge backs, inventory monitoring, and workload reporting.
The maintenance of a flexible, sophisticated institutional biorepository in conjunction with an advanced research histology core facility is vital to all aspects of current and future intra- and extramural clinical, translational, basic, and population-based research efforts at MD Anderson.
|Daver, Naval; Verstovsek, Srdan (2015) Ruxolitinib and DNA methyltransferase-inhibitors: a foray into combination regimens in myelofibrosis. Leuk Lymphoma 56:279-80|
|Burstein, Matthew D; Tsimelzon, Anna; Poage, Graham M et al. (2015) Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clin Cancer Res 21:1688-98|
|Mersch, Jacqueline; Jackson, Michelle A; Park, Minjeong et al. (2015) Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian. Cancer 121:269-75|
|Pugh, Thomas J; Mahmood, Usama; Swanson, David A et al. (2015) Sexual potency preservation and quality of life after prostate brachytherapy and low-dose tadalafil. Brachytherapy 14:160-5|
|Zuo, Zhuang; Maiti, Sourindra; Hu, Shimin et al. (2015) Plasma circulating-microRNA profiles are useful for assessing prognosis in patients with cytogenetically normal myelodysplastic syndromes. Mod Pathol 28:373-82|
|Martin, Neil E; Massey, Laura; Stowell, Caleb et al. (2015) Defining a standard set of patient-centered outcomes for men with localized prostate cancer. Eur Urol 67:460-7|
|Shen, Qi; Ouyang, Juan; Tang, Guilin et al. (2015) Flow cytometry immunophenotypic findings in chronic myelomonocytic leukemia and its utility in monitoring treatment response. Eur J Haematol 95:168-76|
|Massarweh, Nader N; Haynes, Alex B; Chiang, Yi-Ju et al. (2015) Adequacy of the National Quality Forum's Colon Cancer Adjuvant Chemotherapy Quality Metric: Is 4 Months Soon Enough? Ann Surg 262:312-20|
|Garcia-Manero, Guillermo; Khoury, Hanna J; Jabbour, Elias et al. (2015) A phase I study of oral ARRY-614, a p38 MAPK/Tie2 dual inhibitor, in patients with low or intermediate-1 risk myelodysplastic syndromes. Clin Cancer Res 21:985-94|
|Brown, Alaina J; Sun, Charlotte C; Urbauer, Diana et al. (2015) Targeting those with decreased meaning and peace: a supportive care opportunity. Support Care Cancer 23:2025-32|
Showing the most recent 10 out of 2114 publications